CRISPR Therapeutics (CRSP) News

CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

ZUG, Switzerland and BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Morgan Stanley 24

CRISPR TherapeuticsSep 8 12:00

Crispr Therapeutics Maintained at Buy as Lp(a) Program Prospects Support Unchanged $88 Price Target

TipRanksSep 7 22:15

Cathie Wood Says AI Revolution Could Supercharge Global Growth — TSLA, COIN and CRSP Stocks Are Among Her Top Bets

ARK Invest CEO Cathie Wood says the ongoing technological shift mirrors the Industrial Revolution. Outlining her macroeconomic outlook, she said, "rapid real growth is where we're going," expecting

BenzingaSep 7 14:46

Investors Shrug Off Good News for Heart Patients From New Meds -- Barrons.com

By Bill Alpert This year's run in drug stocks gained vigor from new treatments for heart attacks and strokes. Maybe some of those stocks are losing wind. At this past weekend's congress of the

Barron'sSep 2 03:27

Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs

The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive

BenzingaSep 2 00:25

Needham Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $82

Needham analyst Gil Blum maintains $CRISPR Therapeutics(CRSP.US)$ with a buy rating, and maintains the target price at $82.According to TipRanks data, the analyst has a success rate of 46.1% and a

Futu NewsSep 1 17:31

Analysts Are Bullish on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Jazz Pharmaceuticals (JAZZ)

TipRanksSep 1 16:50

Evercore Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $76

Evercore analyst Jonathan Miller maintains $CRISPR Therapeutics(CRSP.US)$ with a buy rating, and maintains the target price at $76.According to TipRanks data, the analyst has a success rate of 59.6%

Futu NewsAug 31 21:32

Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Tenax Therapeutics (TENX) and Belite Bio, Inc. ADR (BLTE)

TipRanksAug 31 19:20

Needham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target

Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $82 price target.

BenzingaAug 31 18:03

William Blair Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating

William Blair analyst Sami Corwin maintains $CRISPR Therapeutics(CRSP.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 58.8% and a total average return of 19.8%

Futu NewsAug 29 03:32

Morgan Stanley Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $60

Morgan Stanley analyst Maxwell Skor maintains $CRISPR Therapeutics(CRSP.US)$ with a hold rating, and maintains the target price at $60.According to TipRanks data, the analyst has a success rate of 75.

Futu NewsAug 29 01:31

CRISPR Therapeutics Presents Phase 1a Data for CTX310 Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

-Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026--Phase 1a clinical data for CTX310 continued to demonstrate robust, dose-dependent

CRISPR TherapeuticsAug 28 12:00

Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.

BenzingaAug 25 21:15

Major breakthroughs in modern mRNA cancer vaccines have ignited market sentiment, suggesting that the revaluation of the biotechnology sector may have only just begun.

Moderna's Phase III clinical trial for melanoma yielded positive results, acting as a catalyst for the entire biotechnology sector. This development drove broad gains in biotechnology ETFs and renewed market confidence in next-generation therapeutic technologies.

Zhitong FinanceAug 25 11:45

Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX), Novavax Inc. (NASDAQ:NVAX) and CRISPR Therapeutics AG (NASDAQ:CRSP) are trending on Thursday.In pre-market trading, RXRX fell 1.42% to $3.45, CRSP

BenzingaAug 20 17:59

Moderna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally — Merck, Pfizer and BioNTech Among MRNA Names Trending Tonight

Several healthcare stocks are trending on Wednesday night after popping earlier in the regular session.mRNA Names Cool Off After Explosive SessionModerna Inc. (NASDAQ:MRNA) shares fell 4.65% to $166.2

BenzingaAug 20 11:29

US Stock Market Close | US Treasury intervenes to support long-term bonds, lifting all three major indices; Moderna surges, igniting a rally in the biopharmaceutical sector, with Merck & Co up over 12% and the S&P Biotechnology ETF rising nearly 6%; Bitco

The S&P 500 closed up 0.21% at 7,707.98, the Nasdaq Composite rose 0.16% to 26,331.09, and the Dow Jones Industrial Average gained 0.22% to 53,463.05, ending a three-day losing streak for all three major indices. Moderna surged 176.97% to hit a record high, while Merck & Co jumped 13%, leading the healthcare sector's gains in the S&P; meanwhile, semiconductor and AI momentum stocks suffered heavy losses, with chip ETFs falling a cumulative 7.7% over two days.

wallstreetcnAug 20 07:02

Biotechs Hit a Post-pandemic High After MRNA Trial Win for Moderna, Merck

Seeking AlphaAug 20 02:38

Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday

U.S. stocks were mixed, with the Dow Jones index gaining over 200 points on Wednesday.Shares of Estee Lauder Companies Inc (NYSE:EL) rose sharply after the company reported better-than-expected

BenzingaAug 19 22:08